Post-IPO Equity - ImmunityBio
Investment Firm
Overview
ImmunityBio is a late-stage immunotherapy startup that is developing treatments to drive immunogenic pathways in the fight against cancer.
Announced Date
Sep 11, 2023
Funding Type
Post Ipo Equity
Highlights
Location
United States, North America
Social
Participant Investors
1
| Investor Name |
|---|
 NantCapital |
Round Details and Background
ImmunityBio raised $270000000 on 2023-09-11 in Post-IPO Equity
ImmunityBio is a late-stage immunotherapy startup that is developing treatments to drive immunogenic pathways in the fight against cancer.
Company Funding History
13
| Announcment Date | Transaction Name | Number Of Investors | Lead Investor | Money Raised |
|---|---|---|---|---|
| Jan 02, 2024 |  Post-IPO Debt - ImmunityBio | 1 | - | 200.0M |
| Jan 02, 2024 | Post-IPO Equity - ImmunityBio | 1 | - | 10.0M |
| Jan 25, 2016 | Private Equity Round - ImmunityBio | - | 57.0M | |
| Jun 02, 2015 | Private Equity Round - ImmunityBio | 1 | - | 75.0M |
Recent Activity
There is no recent news or activity for this profile.